medigraphic.com
ISSN 2954-3835 (Digital)
ISSN 2683-2828 (Impreso)

2021, Número 1

<< Anterior Siguiente >>

Cardiovasc Metab Sci 2021; 32 (1)


Bradicardia temprana en pacientes con COVID-19 y triple terapia

Jacobo-Vargas TB, Orozco-Gutiérrez JJ, Rivero-Martínez JA

Idioma: Inglés [English version]
Referencias bibliográficas: 16
Paginas: 22-31
Archivo PDF: 306.87 Kb.


RESUMEN

Debido a que aún no hay un tratamiento médico efectivo para la COVID-19, se han utilizado medicamentos fuera de indicación como la hidroxicloroquina o cloroquina, lopinavir/ritonavir y/o azitromicina, cuya información de seguridad es limitada con el riesgo de la presencia de efectos adversos cardiacos potenciales. Con la finalidad de contribuir con la información de seguridad del uso de combinación de medicamentos para COVID-19, seguimos la Guía "Consensus based Clinical Case Reporting Guideline Development" desarrollada por la Red EQUATOR (Enhancing the Quality and Transparency of Health Research) para presentar cuatro pacientes, sin patología cardiaca conocida o evidencia de trastornos del ritmo cardiaco, que desarrollaron bradicardia sinusal temprana uno a tres días posteriores al uso concomitante de la triple terapia con hidroxicloroquina, lopinavir/ritonavir y azitromicina, la cual remitió tras la suspensión de uno o más de los medicamentos mencionados. Estos casos contribuyen a mejorar el conocimiento de los problemas de seguridad sobre el uso pasado de medicamentos no aprobados para la COVID-19. Se debe considerar el riesgo de bradicardia con la triple terapia presentada.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Chu C, Cheng V, Hung I, Wong M, Chan K, Kao R et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004; 59: 252-256. doi: 10.1136/thorax.2003.012658.

  2. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30: 269-271. doi: 10.1038/s41422-020-0282-0.

  3. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 56: 105949. doi: 10.1016/j.ijantimicag.2020.105949.

  4. Page RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM et al. Drugs that may cause or exacerbate heart failure. Circulation. 2016; 134: e32-e69. doi: 10.1161/CIR.0000000000000426.

  5. Woosley RL, Heise CW, Gallo T, Tate J, Woosley D, Romero KA. Credible meds [Internet]. Arizona: AZCERT, Inc; 2020 [updated 2020 May 12; cited 2020 May 24]. Available from: https://www.crediblemeds.org/index.php/new-drug-list

  6. Hafeez Y, Grossman SA. Sinus bradycardia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 [cited 2020 July 14]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK493201/

  7. Puelles VG, Lütgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, AllweissL et al. Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med. 2020; 383: 590-592. doi: 10.1056/NEJMc2011400.

  8. UpToDate [Internet]. Waltham MA: UpToDate Inc; Azithromycin (systemic): Drug information, Hydroxychloroquine: Drug information, Lopinavir and ritonavir: Drug information, Dexmedetomidine: Drug information and Furosemide: Drug information; [Accessed on June 05, 2020]. Available from: https://www.uptodate.com/contents/search

  9. Sarayani A, Cicali B, Henriksen CH, Brown JD. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. Res Social Adm Pharm. 2021; 17 (2): 483-486. doi: 10.1016/j.sapharm.2020.04.016.

  10. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020; 75: 2352-2371. doi: 10.1016/j.jacc.2020.03.031.

  11. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323: 1061-1069. doi: 10.1001/jama.2020.1585.

  12. Naksuk N, Lazar S, Peeraphatdit T. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. Eur Heart J Acute Cardiovasc Care. 2020; 9: 215-221. doi: 10.1177/2048872620922784.

  13. Amaratunga EA, Corwin DS, Moran L, Snyder R. Bradycardia in patients with COVID-19: a calm before the storm? Cureus. 2020; 12: e8599. doi 10.7759/cureus.8599.

  14. Hu L, Gong L, Jiang Z, Wang Q, Zou Y, Zhu L. Clinical analysis of sinus bradycardia in patients with severe COVID-19 pneumonia. Crit Care. 2020; 24: 257. doi: 10.1186/s13054-020-02933-3.

  15. Lane JCE, Weaver J, Kostka K, Duarte-Salles T, Abrahao M, Alghoul H et al. Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study. medRxiv [Internet]. 2020 [cited 2020 May 30]. doi: 10.1101/2020.04.08.20054551. Available from: https://www.medrxiv.org/content/10.1101/2020.04.08.20054551v2

  16. Chorin E, Dai M, Shulman E, Wadhwani L, Cohen RB, Barbhaiya C et al. The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin. medRxiv [Internet]. 2020 [cited 2020 May 30]. doi: 10.1101/2020.04.02.20047050. Available from: https://www.medrxiv.org/content/10.1101/2020.04.02.20047050v1




2020     |     www.medigraphic.com